Zi-Qing Tang
Dados Biográficos
| ID | 9999072 |
|---|---|
| NOME | Zi-Qing Tang |
| PRENOMES | Zi-Qing |
| SOBRENOME | Tang |
| ASSINATURA | TANG Z |
| AFILIAÇÕES | Central South University |
| VERIFICADO | Não |
| TOTAL DE OBRAS | 1 |
| TOTAL DE CITAÇÕES | 0 |
| TOTAL COMO AUTOR | 1 |
| TOTAL COMO EDITOR | 0 |
| PRIMEIRO ANO DE PUBLICAÇÃO | 2022 |
| ANO MAIS RECENTE DE PUBLICAÇÃO | 2022 |
| ÍNDICE H | 0 |
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM. Methods: A Markov model was deve…
Sem obras proeminentes nesta página.
Cost-effectiveness of nivolumab plus ipilimumab as first-line treatment for American patients with unresectable malignant pleural mesothelioma
Background: The treatment paradigm of unresectable malignant pleural mesothelioma (MPM) has changed in recent years. Checkmate 743 demonstrate that nivolumab plus ipilimumab showed good clinical benefits compared with chemotherapy in the treatment of MPM. The study is aim to evaluate the cost-effectiveness of Nivolumab plus ipilimumab vs. platinum plus chemotherapy for the first-line treatment of unresectable MPM. Methods: A Markov model was deve…
Cancer (1 obra) · Cancer Immunotherapy and Biomarkers (1 obra) · Chemotherapy (1 obra) · Cost effectiveness (1 obra) · First line treatment (1 obra) · Immunotherapy (1 obra) · Internal Medicine (1 obra) · Ipilimumab (1 obra) · Medicine (1 obra) · Mesothelioma (1 obra)